Literature DB >> 28583857

A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test.

Paul J Wichgers Schreur1, Janusz T Paweska2, Jet Kant3, Jeroen Kortekaas3.   

Abstract

Antibodies specific for Rift Valley fever virus (RVFV) can be detected by diverse methods, including ezyme-linked immunosortbent assay (ELISA) and virus neutralization test (VNT). The VNT is superior in sensitivity and specificity and is therefore considered the gold standard serological assay. Classical VNTs make use of virulent RVFV and therefore have to be performed in biosafety level 3 laboratories. Here, we report the development of a novel VNT that is based on an avirulent RVFV expressing the enhanced green fluorescent protein (eGFP), which can be performed safely outside level 3 biocontainment facilities. Evaluation with a broad panel of experimental sera and field sera demonstrated that this novel VNT is faster and more sensitive than the classical VNT.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4-Segmented; GFP; Rift Valley fever virus; Ruminants; Virus neutralization test

Mesh:

Substances:

Year:  2017        PMID: 28583857     DOI: 10.1016/j.jviromet.2017.06.001

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset.

Authors:  Paul J Wichgers Schreur; Petra Mooij; Gerrit Koopman; Babs E Verstrepen; Zahra Fagrouch; Daniella Mortier; Nikki van Driel; Jet Kant; Sandra van de Water; Willy M Bogers; Carine Punt; Lucien van Keulen; Ernst J Verschoor; Jeroen Kortekaas
Journal:  NPJ Vaccines       Date:  2022-05-18       Impact factor: 9.399

2.  Multimeric single-domain antibody complexes protect against bunyavirus infections.

Authors:  Paul J Wichgers Schreur; Sandra van de Water; Michiel Harmsen; Erick Bermúdez-Méndez; Dubravka Drabek; Frank Grosveld; Kerstin Wernike; Martin Beer; Andrea Aebischer; Olalekan Daramola; Sara Rodriguez Conde; Karen Brennan; Dorota Kozub; Maiken Søndergaard Kristiansen; Kieran K Mistry; Ziyan Deng; Jan Hellert; Pablo Guardado-Calvo; Félix A Rey; Lucien van Keulen; Jeroen Kortekaas
Journal:  Elife       Date:  2020-04-21       Impact factor: 8.140

3.  Development of a Visible Reverse Transcription-Loop-Mediated Isothermal Amplification Assay for the Detection of Rift Valley Fever Virus.

Authors:  Qiuxue Han; Shengnan Zhang; Dongping Liu; Feihu Yan; Hualei Wang; Pei Huang; Jinhao Bi; Hongli Jin; Na Feng; Zengguo Cao; Yuwei Gao; Hang Chi; Songtao Yang; Yongkun Zhao; Xianzhu Xia
Journal:  Front Microbiol       Date:  2020-11-13       Impact factor: 5.640

4.  Large-Scale International Validation of an Indirect ELISA Based on Recombinant Nucleocapsid Protein of Rift Valley Fever Virus for the Detection of IgG Antibody in Domestic Ruminants.

Authors:  Janusz T Pawęska; Petrus Jansen van Vuren; Veerle Msimang; Modu Moustapha Lô; Yaya Thiongane; Leopold K Mulumba-Mfumu; Alqadasi Mansoor; José M Fafetine; Joseph W Magona; Hiver Boussini; Barbara Bażanow; William C Wilson; Michel Pepin; Hermann Unger; Gerrit Viljoen
Journal:  Viruses       Date:  2021-08-19       Impact factor: 5.048

5.  Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021.

Authors:  Keli N Gerken; A Desirée LaBeaud; Henshaw Mandi; Maïna L'Azou Jackson; J Gabrielle Breugelmans; Charles H King
Journal:  PLoS Negl Trop Dis       Date:  2022-01-24

Review 6.  Rift valley fever: diagnostic challenges and investment needs for vaccine development.

Authors:  Velislava Petrova; Paul Kristiansen; Gunnstein Norheim; Solomon A Yimer
Journal:  BMJ Glob Health       Date:  2020-08

7.  Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales.

Authors:  Sara Rodriguez-Conde; Sophie Inman; Viv Lindo; Leanne Amery; Alison Tang; Uche Okorji-Obike; Wenjuan Du; Berend-Jan Bosch; Paul J Wichgers Schreur; Jeroen Kortekaas; Isabel Sola; Luis Enjuanes; Laura Kerry; Katharina Mahal; Martyn Hulley; Olalekan Daramola
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

8.  Vaccine Efficacy of Self-Assembled Multimeric Protein Scaffold Particles Displaying the Glycoprotein Gn Head Domain of Rift Valley Fever Virus.

Authors:  Paul J Wichgers Schreur; Mirriam Tacken; Benjamin Gutjahr; Markus Keller; Lucien van Keulen; Jet Kant; Sandra van de Water; Yanyin Lin; Martin Eiden; Melanie Rissmann; Felicitas von Arnim; Rebecca König; Alexander Brix; Catherine Charreyre; Jean-Christophe Audonnet; Martin H Groschup; Jeroen Kortekaas
Journal:  Vaccines (Basel)       Date:  2021-03-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.